The Germantown, Md.-based company cited positive early feedback on the March launch of its Eversense Bridge Program, which is designed to improve patient access to the company’s Eversense continuous glucose monitoring system.
Senseonics reported losses of -$29.4 million, or -17¢ per share, on sales of $3.4 million for the three months ended March 31, for a bottom-line loss of -32% on sales growth of 16.9% compared with Q1 2018.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.